

1 **Title:** *Plasmodium falciparum* with *pfhrp2/3* deletion not detected in a 2018-2021 malaria longitudinal
2 cohort study in Kinshasa Province, Democratic Republic of the Congo

3 **Running head for use as a header (max 60 characters, including spaces):** *Pfhrp2/3* deletions in a malaria
4 longitudinal study in DRC

5

6 **Authors:** Ruthly François¹, Melchior Mwandagalirwa Kashamuka², Kristin Banek¹, Joseph A. Bala²,
7 Marthe Nkalani², Georges Kihuma², Joseph Atibu², Georges E. Mahilu², Kyaw L. Thwai¹, Ashenafi Assefa¹,
8 Jeffrey A. Bailey³, Rhoel R. Dinglasan⁴, Jonathan J. Juliano¹, Antoinette Tshefu^{2#}, Jonathan B. Parr^{1#*}

9 **Affiliations:** ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, ²Kinshasa School
10 of Public Health, Kinshasa, Democratic Republic of the Congo, ³Brown University, Providence, RI, United
11 States, ⁴University of Florida, Gainesville, FL, United States.

12 #Co-senior authors

13 * Corresponding: Jonathan B. Parr, MD, MPH; 111 Mason Farm Rd, CB#7036, Chapel Hill, NC 27599;
14 jonathan_parr@med.unc.edu; 1-919-445-1132.

15 **Keywords:** Malaria, *Plasmodium falciparum*, hrp2, hrp3, Kinshasa

16 **Word count:** 136 (abstract); 1,004 (body)

17 **Number of figures and tables:** 3 (2 figures, 1 table)

18

19

20

21 **Abstract**

22 Histidine-rich protein 2- (HRP2-) based rapid diagnostic tests (RDTs) are widely used to detect
23 *Plasmodium falciparum* in sub-Saharan Africa. Reports of parasites with *pfhrp2* and/or *pfhrp3* (*pfhrp2/3*)
24 gene deletions in Africa raise concerns about the long-term viability of HRP2-based RDTs. We evaluated
25 changes in *pfhrp2/3* deletion prevalence over time using a 2018-2021 longitudinal study of 1,635
26 enrolled individuals in Kinshasa Province, Democratic Republic of the Congo (DRC). Samples collected
27 during biannual household visits with ≥ 100 parasites/ μL by quantitative real-time PCR were genotyped
28 using a multiplex real-time PCR assay. Among 2,726 *P. falciparum* PCR-positive samples collected from
29 993 participants during the study period, 1,267 (46.5%) were genotyped. No *pfhrp2/3* deletions or
30 mixed *pfhrp2/3*-intact and -deleted infections were identified in our study. *Pfhrp2/3*-deleted parasites
31 were not detected in Kinshasa Province; ongoing use of HRP2-based RDTs is appropriate.

32

33 **Body**

34 Progress toward malaria control and elimination in Africa requires prompt diagnosis and
35 treatment with effective antimalarial drugs. Rapid diagnostic tests (RDTs) are widely used to identify
36 individuals infected with *Plasmodium*; their deployment enabled significant improvements in malaria
37 diagnostic testing across the continent over the past 15 years. The majority of RDTs used to diagnose
38 falciparum malaria in sub-Saharan Africa detect *P. falciparum* histidine-rich protein 2 (HRP2) and its
39 paralog HRP3, encoded by the *pfhrp2* and *pfhrp3* genes, respectively. HRP2-based RDTs are generally
40 more sensitive and heat-stable than RDTs detecting other antigens.¹ However, test-and-treat strategies
41 that rely upon HRP2-based RDTs are threatened by the emergence of *P. falciparum* strains that escape
42 detection due to deletion of the *pfhrp2* and/or *pfhrp3* (*pfhrp2/3*) genes.^{2,3} High prevalence of *pfhrp2/3*-
43 deleted parasites in Eritrea,⁴ Ethiopia,^{5,6} Djibouti,^{7,8} and surrounding countries recently prompted

44 changes in malaria diagnostic testing policies. Reports from sub-Saharan countries outside of the Horn
45 of Africa, however, indicate lower prevalence.⁹

46 The Democratic Republic of the Congo (DRC) has one of the highest malaria burdens in the
47 world, accounting for 12% of global malaria cases and deaths.² In the DRC, we previously reported 6.4%
48 *pfhrp2* deletion prevalence in samples from a 2013-2014 nationally representative cross-sectional
49 survey of asymptomatic children under five years of age.¹⁰ However, no *pfhrp2/3* deletions were
50 observed in our 2017 cross-sectional study of symptomatic children and adults across three DRC
51 provinces.¹¹ These studies were both cross-sectional and did not provide information about how the
52 prevalence of deletions may be changing over time. This study aims to estimate the *pfhrp2/3* deletion
53 prevalence and changes over time in Kinshasa Province, DRC.

54 This study includes samples collected as part of a 2018-2021 longitudinal study of malaria
55 conducted at seven sites across Kinshasa Province, DRC. A total of 1,635 participants were enrolled in
56 one urban neighborhood, three peri-urban villages, and three rural villages (**Figure 1**). Study visits were
57 conducted as part of twice-yearly household surveys in the dry and rainy seasons (active surveillance)
58 and as part of routine care at local health centers (passive surveillance) as previously described.^{12,13} At
59 each visit, a comprehensive questionnaire on malaria symptoms and treatment, and bed net usage was
60 administered. A finger- or heel-prick sample was obtained at each visit for RDT (SD Bioline Ag P.f./Pan
61 RDT [05FK60], Alere, Gyeonggi-do, Republic of Korea, or CareStart, Access Bio, Somerset, U.S.A.) and
62 dried blood spot (DBS) preparation for future molecular investigation. RDT-positive patients were
63 treated according to national guidelines.

64 DNA was extracted from DBS using Chelex-100 and saponin or tween as previously described.
65 ^{14,15} Quantitative real-time PCR (qPCR) targeting the *P. falciparum lactate dehydrogenase (pfldh)* gene
66 was used to estimate *P. falciparum* parasitemia, using serial dilutions of DNA extracted from a mock DBS

67 made with cultured *P. falciparum* 3D7 or FCR3 strain parasites at known parasite density. Samples with \geq
68 100 parasites/ μ L were selected for *pfhrp2/3* deletion identification using a multiplex real-time PCR assay
69 that detects *pfdh*, *pfhrp2*, *pfhrp3*, and human *beta-tubulin* (*HumTuBB*).¹⁶ We used this parasite density
70 threshold to reduce the risk of unintentional misclassification of deletions in the setting of low DNA
71 concentrations.^{17,18} Positive calls required cycle threshold (C_t) values < 35 . Samples positive for
72 *HumTuBB* and *pfdh* but negative for *pfhrp2* or *pfhrp3* were subjected to a confirmatory real-time PCR
73 targeting the *P. falciparum beta-tubulin* (*PfBtubulin*) gene. Deletion calls were limited to samples
74 positive for *HumTuBB* and both single-copy *P. falciparum* genes (*pfdh* and *pftubulin*), but negative for
75 *pfhrp2* and/or *pfhrp3*. Mixed infections of *pfhrp2/3*-intact and -deleted strains were defined
76 conservatively as samples in which (*pfhrp2* C_t - *pfdh* C_t) > 3 or (*pfhrp3* C_t - *pfdh* C_t) > 3 . All assays included
77 *P. falciparum* 3D7, DD2, and HB3 strain DNA as wildtype, *pfhrp2*-deleted, and *pfhrp3*-deleted controls,
78 respectively. All participants provided informed consent. Ethical approval for this study was granted by
79 the Institutional Review Boards of the University of North Carolina-Chapel Hill and the Kinshasa School
80 of Public Health.

81 A total of 1,267 samples collected from 649 individuals in 179 households between 2018 and
82 2021 were included in this study (**Figure 2**). Among these, the median number of *P. falciparum*
83 infections with ≥ 100 parasites/ μ L detected per participant was 2.0 (IQR: 1-3). The median age at
84 enrollment in 2018 was 9 years old (IQR: 5-15 years old); 48.8% reported female gender. At the time of
85 enrollment, 48.7% reported malaria in the preceding 6 months, and 42.7% of those reported more than
86 one episode in that 6-month period. The median household size was 8 (IQR: 6-10), with high bed net
87 coverage across the study population (90.2%). The baseline characteristics of the study population are
88 summarized in **Table 1**.

89 All 1,267 samples had detectable human DNA as indicated by amplification of *HumTuBB* with C_t
90 < 35 . The multiplex PCR confirmed *P. falciparum* parasitemia in all but 2 samples which failed to amplify

91 *pfl dh*. Both *pfhrp2* and *pfhrp3* were negative in one sample ($C_t > 35$ for both gene targets). However,
92 *pfl dh* was negative in the multiplex assay and *Pftubulin* negative in follow-up testing, indicating that the
93 original *pfl dh* qPCR result was a false-positive. Thus, this sample did not meet criteria to be considered a
94 *pfhrp2/3*-deleted parasite. There were no mixed infections of *pfhrp2/3*-intact and -deleted strains
95 identified in our study population.

96 Overall, we did not find evidence of *pfhrp2/3* deletion in parasites sampled during our
97 longitudinal cohort in Kinshasa Province. Our conservative approach to calling *pfhrp2/3* deletions
98 prevents us from detecting low-density infections and thus could underestimate the true prevalence of
99 these strains. These study results differ from our previous DRC *pfhrp2/3* deletion prevalence estimates;
100 this discrepancy could be attributed to spatial heterogeneity in prevalence, incorrect deletion calls due
101 to laboratory artifact, or different approaches used to identify *pfhrp2/3* deletions. However, our finding
102 of no deletions is in line with our more recent study of symptomatic individuals and a similar study of
103 asymptomatic and symptomatic school-aged children that showed no to little evidence of *pfhrp2/3*
104 deletion in the DRC.^{11,19} Together, these results support the continued use of HRP2-based RDTs for the
105 diagnosis of malaria in Kinshasa Province, DRC.

106

107 **Acknowledgements**

108 The authors thank the study participants and field teams who conducted study visits. They also wish to
109 express their gratitude to the late Prof. Steven Meshnick for mentorship and his role in the longitudinal
110 study upon which this analysis was based. The following reagents were obtained through BEI Resources,
111 NIAID, NIH: Genomic DNA from *P. falciparum* strain 3D7, MRA-102G, contributed by Daniel J. Carucci; *P.*
112 *falciparum* strain HB3, MRA-155G, contributed by Thomas E. Wellems; *P. falciparum* strain Dd2, MRA-
113 150G, contributed by David Walliker.

114

115 **Financial support**

116 This study was funded by R01AI132547 to JJJ and RRD, with partial support from R01AI129812 to AKT,
117 R01AI139520 to JAB and a supplement to RF, T32AI070114 to KB, K24AI134990 to JJJ, and an
118 ASTMH/Burroughs-Wellcome Fund award to JBP.

119

120 **Disclosures**

121 JBP reports research support from Gilead Sciences and non-financial support from Abbott Laboratories,
122 outside the scope of this manuscript.

123 **Figure 1.** Study sites in Kinshasa Province, DRC

124

125 **Figure 2.** Flow diagram for the detection of *pfhrp2/3* deletion in 1,267 samples from 649 participants in
126 phase two of the longitudinal study (2018-2021) in Kinshasa Province, DRC

127 **Table 1.** Baseline characteristics of the study population included in this analysis (1,267 samples with \geq
 128 100 *Plasmodium falciparum* parasites/ μ L from 649 participants), during enrollment in the Kinshasa
 129 longitudinal study.

	N = 649 participants
Age in years, median (IQR)	9 (5-15)
Age strata, n (%)	
< 1 year	15 (2.3)
1-5 years	166 (25.6)
6-10 years	191 (29.5)
11-15 years	119 (18.4)
16-25 years	76 (11.7)
> 25 years	81 (12.5)
Sex, n (%)	
Female	317 (48.8)
Male	332 (51.2)
Malaria in previous 6 months, n (%)	
No	311 (51.3)
Yes-once	169 (27.9)
Yes-many	126 (20.8)
Slept under bed net previous night, n (%)	
No	47 (9.8)
Yes	432 (90.2)
Household size, median (IQR)	8 (6-10)
Site of residence, n (%)	
Bu (rural)	87 (13.4)
Impuru (rural)	123 (19.0)
Pema (rural)	121 (18.6)
Ngamanzo (peri-urban)	108 (16.6)
Iye (peri-urban)	60 (9.2)
Kimpoko (peri-urban)	122 (18.8)
Lingwala (urban)	28 (4.3)
Number of samples per participant, median (IQR)	2 (1-3)

130

131

132

133

134

135 **Co-author contact information:**

136 Ruthly François: University of North Carolina at Chapel Hill, Chapel Hill, NC, United States;

137 ruthly_francois@med.unc.edu

138 Melchior Mwandagalirwa Kashamuka²: Kinshasa School of Public Health, Kinshasa, Democratic Republic
139 of the Congo; mkashamuka@yahoo.com

140 Kristin Banek¹: University of North Carolina at Chapel Hill, Chapel Hill, NC, United States;

141 kristin_banek@med.unc.edu

142 Joseph A. Bala²: Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo;

143 jalexandrebala@yahoo.fr

144 Marthe Nkalani²: Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo;

145 marthenkalani@gmail.com

146 Georges Kihuma²: Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo;

147 georgeskihuma@gmail.com

148 Joseph Atibu²: Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo;

149 fejef576@gmail.com

150 Georges E. Mahilu²: Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo;

151 emomahilu@gmail.com

152 Kyaw L. Thwai¹: University of North Carolina at Chapel Hill, Chapel Hill, NC, United States;

153 thwai@email.unc.edu

154 Ashenafi Assefa¹: University of North Carolina at Chapel Hill, Chapel Hill, NC, United States;

155 ashenafi_assefa@med.unc.edu

- 156 Jeffrey A. Bailey³: Brown University, Providence, RI, United States; jeffrey_bailey@brown.edu
- 157 Rhoel R. Dinglasan⁴: University of Florida, Gainesville, FL, United States; rdinglasan@epi.ufl.edu
- 158 Jonathan J. Juliano: University of North Carolina at Chapel Hill, Chapel Hill, NC, United States;
- 159 jonathan_juliano@med.unc.edu
- 160 Antoinette Tshetu^{2*}: Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo;
- 161 antotshe@yahoo.com
- 162 Jonathan B. Parr: University of North Carolina at Chapel Hill, Chapel Hill, NC, United States;
- 163 jonathan_parr@med.unc.edu

164 **References**

- 165 1. Chiodini PL, Bowers K, Jorgensen P, Barnwell JW, Grady KK, Luchavez J, et al. The heat stability of
166 Plasmodium lactate dehydrogenase-based and histidine-rich protein 2-based malaria rapid
167 diagnostic tests. *Trans R Soc Trop Med Hyg.* 2007;101(4).
- 168 2. Geneva: World Health Organization. World Malaria Report 2021. *Angewandte Chemie*
169 *International Edition*, 6(11), 951–952. 2021.
- 170 3. Geneva: World Health Organization. Statement by the Malaria Policy Advisory Group on the
171 urgent need to address the high prevalence of pfhrp2/3 gene deletions in the Horn of Africa and
172 beyond. [Internet]. 2021. Available from: [https://www.who.int/news/item/28-05-2021-](https://www.who.int/news/item/28-05-2021-statement-by-the-malaria-policy-advisory-group-on-the-urgent-need-to-address-the-high-prevalence-of-pfhrp2-3-gene-deletions-in-the-horn-of-africa-and-beyond)
173 [statement-by-the-malaria-policy-advisory-group-on-the-urgent-need-to-address-the-high-](https://www.who.int/news/item/28-05-2021-statement-by-the-malaria-policy-advisory-group-on-the-urgent-need-to-address-the-high-prevalence-of-pfhrp2-3-gene-deletions-in-the-horn-of-africa-and-beyond)
174 [prevalence-of-pfhrp2-3-gene-deletions-in-the-horn-of-africa-and-beyond](https://www.who.int/news/item/28-05-2021-statement-by-the-malaria-policy-advisory-group-on-the-urgent-need-to-address-the-high-prevalence-of-pfhrp2-3-gene-deletions-in-the-horn-of-africa-and-beyond)
- 175 4. Berhane A, Anderson K, Mihreteab S, Gresty K, Rogier E, Mohamed S, et al. Major threat to
176 malaria control programs by plasmodium falciparum lacking histidine-rich protein 2, Eritrea.
177 *Emerg Infect Dis.* 2018;24(3).
- 178 5. Feleke SM, Reichert EN, Mohammed H, Brhane BG, Mekete K, Mamo H, et al. Plasmodium
179 falciparum is evolving to escape malaria rapid diagnostic tests in Ethiopia. *Nat Microbiol.*
180 2021;6(10).
- 181 6. Alemayehu GS, Blackburn K, Lopez K, Cambel Dieng C, Lo E, Janies D, et al. Detection of high
182 prevalence of Plasmodium falciparum histidine-rich protein 2/3 gene deletions in Assosa zone,
183 Ethiopia: implication for malaria diagnosis. *Malar J.* 2021;20(1).
- 184 7. Iriart X, Menard S, Chauvin P, Mohamed HS, Charpentier E, Mohamed MA, et al. Misdiagnosis of
185 imported falciparum malaria from African areas due to an increased prevalence of pfhrp2/pfhrp3

- 186 gene deletion: the Djibouti case. Vol. 9, Emerging Microbes and Infections. 2020.
- 187 8. Rogier E, McCaffery JN, Mohamed MA, Herman C, Nace D, Daniels R, et al. Plasmodium
188 falciparum pfhpr2 and pfhpr3 Gene Deletions and Relatedness to Other Global Isolates, Djibouti,
189 2019-2020. Emerg Infect Dis [Internet]. 2022;28(10):2043–50. Available from: www.cdc.gov/
- 190 9. Thomson R, Parr JB, Cheng Q, Chenet S, Perkins M, Cunningham J. Prevalence of plasmodium
191 falciparum lacking histidine-rich proteins 2 and 3: A systematic review. Vol. 98, Bulletin of the
192 World Health Organization. 2020.
- 193 10. Parr JB, Verity R, Doctor SM, Janko M, Carey-Ewend K, Turman BJ, et al. Pfhpr2 -Deleted
194 Plasmodium falciparum Parasites in the Democratic Republic of the Congo: A National Cross-
195 sectional Survey. J Infect Dis. 2017;216(1):36–44.
- 196 11. Parr JB, Kieto E, Phanzu F, Mansiangi P, Mwandagilirwa K, Mvuama N, et al. Analysis of false-
197 negative rapid diagnostic tests for symptomatic malaria in the Democratic Republic of the Congo.
198 Sci Rep. 2021;11(1).
- 199 12. Mwandagilirwa MK, Levitz L, Thwai KL, Parr JB, Goel V, Janko M, et al. Individual and household
200 characteristics of persons with Plasmodium falciparum malaria in sites with varying endemicities
201 in Kinshasa Province, Democratic Republic of the Congo. Malar J. 2017;16(1).
- 202 13. Carrel M, Kim S, Mwandagilirwa MK, Mvuama N, Bala JA, Nkalani M, et al. Individual, household
203 and neighborhood risk factors for malaria in the Democratic Republic of the Congo support new
204 approaches to programmatic intervention. Heal Place. 2021;70.
- 205 14. Plowe C V., Djimde A, Bouare M, Doumbo O, Wellems TE. Pyrimethamine and proguanil
206 resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: Polymerase
207 chain reaction methods for surveillance in Africa. Am J Trop Med Hyg. 1995;52(6).

- 208 15. Teyssier NB, Chen A, Duarte EM, Sit R, Greenhouse B, Tessema SK. Optimization of whole-
209 genome sequencing of *Plasmodium falciparum* from low-density dried blood spot samples. *Malar*
210 *J.* 2021;20(1).
- 211 16. Grignard L, Nolder D, Sepúlveda N, Berhane A, Mihreteab S, Kaaya R, et al. A novel multiplex
212 qPCR assay for detection of *Plasmodium falciparum* with histidine-rich protein 2 and 3 (pfrhp2
213 and pfrhp3) deletions in polyclonal infections. *EBioMedicine.* 2020;55.
- 214 17. Parr JB, Anderson O, Juliano JJ, Meshnick SR. Streamlined, PCR-based testing for pfrhp2- and
215 pfrhp3-negative *Plasmodium falciparum*. *Malar J.* 2018;17(1).
- 216 18. Beshir KB, Parr JB, Cunningham J, Cheng Q, Rogier E. Screening strategies and laboratory assays
217 to support *Plasmodium falciparum* histidine-rich protein deletion surveillance: where we are and
218 what is needed [Internet]. Vol. 21, *Malaria Journal.* 2022. p. 201. Available from:
219 <https://doi.org/10.1186/s12936-022-04226-2>
- 220 19. Nundu SS, Arima H, Simpson S V, Chitama B-YA, Munyeku YB, Muyembe J-J, et al. Low prevalence
221 of *Plasmodium falciparum* parasites lacking pfrhp2/3 genes among asymptomatic and
222 symptomatic school-age children in Kinshasa, Democratic Republic of Congo. *Malar J* [Internet].
223 2022;21(1):126. Available from: <https://doi.org/10.1186/s12936-022-04153-2>

224

